

Nanologica AB Changes Dates for Interim Report

Nanologica's interim report for Q2 2026 will be published on Monday 31 August, instead of 20 August as previously announced.

As a result of the acquisition of Syntagon, the company is carrying out an extended validation of the consolidated financial statements.

For further information, please contact

Johanna Westerberg

Director IR, Communications and Marketing

johanna.westerberg@nanologica.com

+46 72 211 21 90

About Nanologica AB (publ)

Nanologica is a Swedish life science group that offers advanced solutions in the development, manufacture and purification of pharmaceutical substances. By combining expertise in materials science, nanotechnology, and chemical process development, with services in contract development and manufacturing, Nanologica provides an integrated platform that supports the entire value chain from early development to commercial production of pharmaceutical substances. Nanologica's offering enables efficient and scalable production of drug substances, with particular strength within complex molecules and peptide-based drugs, such as treatments for diabetes and obesity. The company positions itself as a long-term partner to the pharmaceutical industry, with the goal of enabling more patients around the world to have access to life-saving treatments and cost-effective medicines. The Group has about 70 employees and is headquartered in Södertälje. Nanologica's share (ticker NICA) has been listed on Nasdaq Stockholm's main market since 2022. For further information, please visit www.nanologica.com.

Attachments

[Nanologica AB Changes Dates for Interim Report](#)